A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2017
At a glance
- Drugs TG 1050 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Transgene
- 17 Oct 2016 According to Transgene media release, First Patient Randomized in Multiple Dose Cohort and first data readout is expected in second half of 2017.
- 26 Sep 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2019.
- 05 Sep 2016 According to a Transgene media release, the company expects the first data readout in second half of 2017.